Melissa Kristen Frey MD
Gynecologic Oncology
Director of Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine Associate Professor of Gynecologic Oncology, Weill Cornell Medicine
525 E 68th St# 122New York, NY 10065
Overview of Dr. Frey
Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine / NewYork Presbyterian Hospital. Dr. Frey’s clinical care and research focus on the management of individuals with hereditary cancer syndromes (e.g. BRCA1, BRCA2, Lynch syndrome) and strong family history of breast and gynecologic cancers. She performs gynecologic cancer risk-reducing surgeries and is the principal investigator on several large trials aimed at cancer prevention among high-risk individuals. Dr. Frey has presented her research at national and international meetings and has more than 150 publications in peer-reviewed scientific journals.
Education & Training
NYU Grossman School of MedicineFellowship, Gynecologic Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 2009 - 2013
Weill Cornell MedicineClass of 2009
Certifications & Licensure
NY State Medical License 2013 - 2028
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- FaCT Trial (Facilitated Cascade Testing Trial) Start of enrollment: 2021 Jul 21
Publications & Presentations
PubMed
- The Impact of Chatbot Type and Normative Messaging on Chatbot Usage Intention Based on the Health Technology Acceptance Model: Randomized Controlled Trial.Yi Liao, Anne Madeo, Caitlin G Allen, Melissa K Frey, Whitney Maxwell
Journal of Medical Internet Research. 2026-09-15 - Lights genes action: Video strategy forpatient education.Tina Karimaghaie, Genevieve Fasano, Steve Lopez, Samantha Min, Laura Keenahan
Gynecologic Oncology Reports. 2026-08-01 - Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Hui-Hsuan Kuo, Bhavneet Bhinder, Hamza N Gokozan, Kathryn Gorski, Pooja Chandra
Science Advances. 2026-06-26
Journal Articles
- Prevalence of Nonfounder BRCA1/2 Mutations in Ashkenazi Jewish Patients Presenting for Genetic Testing at a Hereditary Breast and Ovarian Cancer CenterKevin Holcomb, Rohini V Kopparam, Melissa K Frey, Thomas Caputo, Cancer
Authored Content
- Articles & IssuesDecember 2018
Press Mentions
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast DensityOctober 1st, 2025- What You Should Know About Ovarian Cancer VaccinesNovember 16th, 2024
- Faster, Easier, and More Anxiety-Inducing: Are DHTs Harming Patients' Mental Health?February 2nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
